ACTICCA-1

ACTICCA-1 is an international multi centre trial, and is currently open in a few locations in the UK, and planned to open in 20+.

For more details, see:

https://www.ukctg.nihr.ac.uk/ and search for:  ACTICCA-1
and:
https://clinicaltrials.gov/ct2/show/NCT02170090

Lead investigator on the ACTICCA-1 trial in the UK:
Professor John Bridgewater
Medical Oncologist, University College Hospital London

Tel: 020 3447 9093
Fax: 020 3447 9055
Email: j.bridgewater@ucl.ac.uk

UCL Cancer Institute
72 Huntley Street
London   WC1E 6AA

The BILCAP Study
Following the result of the long running BILCAP study, those who have undergone a resection for their cholangiocarcinoma or gall bladder cancer, and who fit the eligibility criteria, are now offered Capecitabine chemotherapy.

ACTICCA-1 is a randomized Phase III trial comparing Gemcitabine and Cisplatin against Capecitabine alone (standard treatment).

For more information on the BILCAP result, please see: http://ammf.org.uk/2017/05/18/bilcap-results-show-chemo-improves-survival  And:http://ammf.org.uk/2017/06/09/the-bilcap-study-results/

In this video Dr John Marshall of Georgetown University, and Professor John Primrose of the University of Southampton, discuss the practice-changing findings of the BILCAP study which investigated adjuvant capecitabine for biliary tract cancer (cholangiocarcinoma).  The pan-European study that Professor Primrose refers to (6:09 into the interview) is the ACTICCA-1 trial.


Back to previous page